COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,051 Articles (22,627 medRxiv, 8,424 bioRxiv)

Most recent first Previous |  Page 958: Articles 9571-9580  | Next

Should healthcare workers with SARS-CoV-2 household exposures work? A Cohort Study.
Quach, C., Blanchard, A. C., Lamarche, J., Audy, N., Lamarre, V.
10.1101/2022.01.23.22269719 — Posted: 2022-01-24
Effectiveness of BBV152 vaccine against SARS-CoV-2 infections, hospitalizations, and deaths among healthcare workers in the setting of high delta variant transmission in New Delhi, India
Malhotra, S., Mani, K., Lodha, R., Bakhshi, S., Mathur, V. P., Gupta, P., Kedia, S., Sankar, J., Kumar, P., Kumar, A., Ahuja, V., Sinha, S., Guleria, R., COVID Reinfection AIIMS Consortium
10.1101/2022.01.22.22269701 — Posted: 2022-01-24
Values and preferences of the general population in Indonesia in relation to COVID-19 self-testing: A cross-sectional survey
Thomas, C., Shilton, S., Thomas, C., Batheja, D., Goel, S., Mone Iye, C., Ivanova Reipold, E., Martinez-Perez, G. Z.
10.1101/2022.01.23.22269718 — Posted: 2022-01-24
Modelling preventive measures and their effect on generation times in emerging epidemics
Favero, M., Scalia Tomba, G., Britton, T.
10.1101/2022.01.24.22269757 — Posted: 2022-01-24
COVID-19 vaccines effectiveness against symptomatic SARS-CoV-2 Delta variant infection: a population-based case-control study in St. Petersburg, Russia
Barchuk, A., Bulina, A., Cherkashin, M., Berezina, N., Rakova, T., Kuplevatskaya, D., Stanevich, O., Skougarevskiy, D., Okhotin, A.
10.1101/2022.01.24.22269714 — Posted: 2022-01-24 Discussion: Onsite
Post-COVID-19 Memory Impairment: Prevalence and Associated Factors
Ahmed, M., Roy, S., Chowdhury, S., Islam, A. M. K., Akhter, S., Iktidar, M. A., Hawlader, M. D. H.
10.1101/2022.01.23.22269525 — Posted: 2022-01-24
Effectiveness of Pfizer-BioNTech Vaccine Against COVID-19 Associated Hospitalizations among Lebanese Adults >=75 years- Lebanon, April-May 2021
Farah, Z., Haddad, N., Abou El-Naja, H., Saleh, M., Mrad, P., Ghosn, N.
10.1101/2022.01.19.22269514 — Posted: 2022-01-24
Nasally-delivered interferon-{lambda} protects mice against upper and lower respiratory tract infection of SARS-CoV-2 variants including Omicron
Chong, Z., Karl, C. E., Halfmann, P. J., Kawaoka, Y., Winkler, E. S., Yu, J., Diamond, M. S.
10.1101/2022.01.21.477296 — Posted: 2022-01-24 Discussion: Offsite
Significance of the RBD mutations in the SARS-CoV-2 Omicron: from spike opening to antibody escape and cell attachment
Hossen, M. L., Baral, P., Sharma, T., Gerstman, B. S., Chapagain, P. P.
10.1101/2022.01.21.477244 — Posted: 2022-01-24
The N764K and N856K mutations in SARS-CoV-2 Omicron S protein generate potential cleavage sites for SKI-1/S1P protease
maaroufi, H.
10.1101/2022.01.21.477298 — Posted: 2022-01-24

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).